Your session is about to expire
← Back to Search
Lu-DOTATATE for Neuroendocrine Cancer
Study Summary
This trial will evaluate the efficacy and safety of Lutetium-177 Octreotate, a treatment for neuroendocrine tumors, in 195 patients. Eligible patients will undergo a diagnostic Ga 68 PET scan, and those who show somatostatin will receive 4 cycles of Lu-DOTATATE treatment. Dose adjustment will be made based on individualized dosimetry, as well as creatinine clearance and hematological parameters. Patients will be evaluated for progression free survival at 12 months from last dose. Patients who are negative for somatostatin will not receive treatment but will be followed until progression and acts as control
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am eligible for a potentially curative surgery or targeted liver therapy.My case has been reviewed by a tumor board for clinical trial suitability.I am eligible for surgery to remove or reduce my cancer.I haven't had radiation on the cancer we're targeting in the last 3 months.I am willing and able to follow the study's schedule and procedures.I have received radiation therapy to a large portion of my bone marrow.My brain metastases have been stable for 6 months or more after treatment.I have another cancer that has worsened in the past 3 years.I haven't had certain cancer treatments in the last 4 weeks.My scans show my cancer has grown in the last 6 months.My recent liver tests are within the normal range.My cancer has spread to my bones significantly, but I am under close blood monitoring.My diabetes is not under control.I am 18 years old or older.I have had treatment with radioactive drugs before.I do not have health issues like urinary incontinence that could affect my treatment.I can take care of myself but might not be able to do heavy physical work.My tumor is confirmed to be neuroendocrine through a biopsy.I am not pregnant or breastfeeding and agree to use birth control during the study.
- Group 1: Lutetium-177 Octreotate
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any open spots for participating in this experiment?
"This clinical trial is not admitting patients at this time. Initially posted on July 15th 2016, and most recently updated April 7th 2022, it has been concluded for the moment. If you are seeking other opportunities to participate in medical trials, there are 166 active studies involving neuroendocrine tumors and 42 open studies using Lutetium-177 Octreotate currently recruiting participants."
How many individuals have been enrolled in this clinical trial?
"Unfortunately, the deadline for this study has already passed. Initially posted on July 15th 2016 and last edited April 7th 2022, no further candidates are being accepted. If you're seeking other trials in a similar vein, 166 experiments are currently recruiting patients with neuroendocrine tumors as well as 42 studies using Lutetium-177 Octreotate treatments."
Could you elaborate on what other experiments have been done using Lutetium-177 Octreotate?
"Currently, 42 trials are actively researching the efficacy of Lutetium-177 Octreotate and 3 of those studies have reached Phase 3. Across 279 research centres spread out throughout Gothenburg and Iowa, scientists continue to investigate this promising treatment."
Share this study with friends
Copy Link
Messenger